The potential to modify a severe DMD disease using a truncated dystrophin molecule was initially suggested by the existence of mildly progressing patients with BMD who express mutant dystrophin proteins missing most of the rod domain (55, 56). Here, DMD is linked to Duchenne muscular dystrophy.